You are about to be redirected to a site intended for people with primary HLH or their caregivers.
You are being redirected to a third party website.
Sobi takes no responsibility for the content of this website.
The most commonly reported adverse reactions (≥ 10%) in the Gamifant® (emapalumab-lzsg) pivotal trial included:
|Adverse reactions||Gamifant (N=34)||Adverse reactions||Gamifant (N=34)|
Primary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition that mostly affects children, but can also occur in adults and teenagers.3-6
is given as an intravenous infusion twice a week until hematopoietic stem cell transplantation (HSCT) is performed.1
Download the Start Form now or contact Gamifant Patient Services at 833.597.6530.